Matthew E. Spector
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (23)
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2026
STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.
Year:
2026
Background: The updated American Joint Committee on Cancer (AJCC) 8th Edition staging manual restructured nodal classification and staging by placing less prognostic emphasis on nodal metastases for human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). However, there was no change for HPV-negative OPSCC. The purpose of our study is to examine the impact of nodal metastases on survival in HPV-negative OPSCC. Methods: HPV-negative OPSCC was queried from the National Cancer Database (NCDB) and Surveillance, Epidemiology and End Results program (SEER) databases. Univariable and multivariable models were utilized to determine the impact of nodal status on overall survival. These patients were reclassified according to AJCC 8 HPV-positive criteria (TNM 8+ ) and risk stratification was quantified with C-statistic. Results: There were 11,147 cases of HPV-negative OPSCC in the NCDB and 3,613 cases in SEER that were included in the nodal classification analysis. Unlike nonoropharyngeal malignancies, increased nodal stage is not clearly associated with survival for patients with OPSCC independent of HPV status. When the TNM 8+ was applied to HPV-negative patients, there was improved concordance in the NCDB cohort, 0.561 (plus minus) 0.004 to 0.624 (plus minus) 0.004 (difference +0.063) and the SEER cohort, 0.561 (plus minus) 0.008 to 0.625 (plus minus) 0.008 (difference +0.065). Conclusions: We demonstrated a reduced impact of nodal metastasis on OPSCC survival, independent of HPV status and specific to OPSCC. Impact: We demonstrate, for the first time that when nodal staging is deemphasized as a part of overall staging, we see improved concordance and risk stratification for HPV-negative OPSCC. The exact mechanism of this differential impact remains unknown but offers a novel area of study.
Year:
2025
Odds ratios (OR) and p values for multi-variable models for acute and late toxicity outcomes including covariates of p16+ OPSCC vs LAHNSCC, primary tumor volume (GTVp) and RT boost volume treated.
Year:
2025
KM curves of average patient p16+ and p16- LRF outcomes. Plot for estimated incidence of loco-regional failure (LRF) with the median boost volume (6.9cc) and GTV primary (54.8cc) for: p16+ OPSCC (left panel) and LAHNSCC (right panel).
Year:
2025
Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Year:
2025
Comparison of t-TMB and CNV scores by clinicopathologic variables in overall cohort. Data shown as median (range) or n (%) for continuous and categorical variables, respectively. Wilcoxon Rank-Sum and Kruskal-Wallis tests used for comparison of categorical and continuous variables, respectively. Additionally, we saw no correlation between primary tumor Breslow depth (mm) and t-TMB (Pearson’s r = -0.131, [95% CI: - 0.412 – 0.173], p = 0.397) or CNV score (Pearson’s r = -0.102, [95% CI: - 0.387 – 0.201], p = 0.511). a Data for primary tumor LVI and Breslow depth available for 45 of 54 (83.3%) patients.
Year:
2025
Kaplan-Meier curves for MCC-specific survival by clinicopathologic variables. Patient sex (A), primary tumor site (B), AJCC 8th edition overall (C) and nodal (D) stage, tumor MCPyV status (E), and MCPyV physical state (for VP-MCC tumors) (F).
Year:
2025
Scatter plot illustrating the correlation between the number of MCPV alterations per tumor and the corresponding number of MCPV reads and Variant Allele Frequency (VAF) plots for all single nucleotide variants and insertions/deletions identified in the cohort.
Year:
2025
Merkel cell carcinoma (MCC) is an aggressive disease with poor survival outcomes and increasing incidence. There is a clear and present need for enhanced understanding of cellular mechanisms of tumorigenesis, validation of robust genetic signatures predictive of aggressive disease, and novel informatics tools to simplify analysis of Merkel cell polyomavirus (MCPyV)–host genome interactions. Genomic DNA was harvested from 54 MCC tumors for exome sequencing and in-depth genetic profiling of a 226-gene panel. We further developed a robust informatics package (MCPyViewer) optimized for MCPyV integration site analysis with graphical output to simplify usability for end users. Finally, we assessed the prognostic impact of specific genetic signatures on MCC-specific survival in our cohort. Our study included 54 patients ( n = 44 MCPyV positive), 11 (20.4%) of whom had died of MCC at last follow-up. Human genes altered at high frequency included LRP1B ( n = 10, 18.5%), FAT1 ( n = 9, 16.7%), KMT2D ( n = 9, 16.7%), and RB1 ( n = 7, 13.0%). In 36 of 44 (81.8%) MCPyV-positive tumors, we identified viral integration into the human genome with a median of two events per tumor. In six tumors, MCPyV integrated into Catalogue of Somatic Mutations in Cancer tier 1 or tier 2 cancer-related human genes. Implications: A combined genomics score incorporating tumor mutational burden and copy-number variation was strongly prognostic of MCC-specific survival controlling for lymph node metastases and tumor MCPyV status; thus, our study adds critical understanding to prognostic markers and tumorigenic mechanisms in MCC.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (24)
Thomas Carey
Professor
University of Michigan Medical School
Heath Skinner
Professor & Chair
University of Pittsburgh
Steven B. Chinn
Assistant Professor
University of Michigan
Ryan Mills
Professor
University of Michigan
Michelle M. Chen
Stanford University
Keith Casper
-
Matthew J. Schipper
University of Michigan
Kelly L. Harms
University of Michigan
Gregory Wolf
Professor
University of Michigan
Peter Harris
Staff Scientist
Washington University in St. Louis
Aadel A. Chaudhuri
Washington University School of Medicine
Paul Swiecicki
University of Michigan
Sidharth V. Puram
Washington University School of Medicine
Yue Cao
University of Michigan
Andrew Rosko
University of Michigan
THEODORE S. LAWRENCE
Chair, Professor
University of Michigan
Jose P. Zevallos
University of Pittsburgh Medical Center
Catherine Haring
Assistant Professor
Ohio State University
Robert Ferris
UPMC Endowed Professor
University of Pittsburgh School of Medicine
Christopher Bichakjian
Professor and Chair
University of Michigan
Carol Bradford
Dean
Ohio State University
J. Chad Brenner
Director Head and Neck Oncology Program
University of Michigan
Wade Thorstad
Professor
Washington University School of Medicine
Scott McLean
Clinical Associate Professor
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.